Bentol may be available in the countries listed below.
Ingredient matches for Bentol
Sulfadiazine silver (a derivative of Sulfadiazine) is reported as an ingredient of Bentol in the following countries:
- Bangladesh
International Drug Name Search
Bentol may be available in the countries listed below.
Sulfadiazine silver (a derivative of Sulfadiazine) is reported as an ingredient of Bentol in the following countries:
International Drug Name Search
Thriostaxil may be available in the countries listed below.
Roxithromycin is reported as an ingredient of Thriostaxil in the following countries:
International Drug Name Search
Naletal may be available in the countries listed below.
Cilostazol is reported as an ingredient of Naletal in the following countries:
International Drug Name Search
Hytacand Orifarm may be available in the countries listed below.
Candesartan cilexetil (a derivative of Candesartan) is reported as an ingredient of Hytacand Orifarm in the following countries:
Hydrochlorothiazide is reported as an ingredient of Hytacand Orifarm in the following countries:
International Drug Name Search
Coquinone may be available in the countries listed below.
Ubidecarenone is reported as an ingredient of Coquinone in the following countries:
International Drug Name Search
Corensoul may be available in the countries listed below.
Tiaramide hydrochloride (a derivative of Tiaramide) is reported as an ingredient of Corensoul in the following countries:
International Drug Name Search
LIQUID Oxygen
Oxygen, REFRIGERATED LIQUID U.S.P. UN 1073 RX ONLY Oxygen 2
KEEP CONTAINER UPRIGHT
FOR LIQUID WITHDRAWAL WEAR FACE SHIELD and GLOVES
USE HAND TRUCK
DO NOT DROP
ALWAYS KEEP CONTAINER IN UPRIGHT POSITION.
WARNING: EXTREMELY COLD, OXIDIZING LIQUID AND GAS UNDER PRESSURE. VIGOROUSLY ACCELERATES COMBUSTION. COMBUSTIBLES IN CONTACT WITH LIQUID Oxygen MAY EXPLODE ON IGNITION OR IMPACT. CAN CAUSE SEVERE FROSTBITE. Keep oil, grease, and combustibles away. Use only with equipment cleaned for Oxygen service. Store and use with adequate ventilation. Do not get liquid in eyes, on skin, or clothing. For liquid withdrawal, wear face shield and gloves. Do not drop. Use suitable hand truck for container movement. Avoid spills. Do not walk on or roll equipment over spills. Cylinder temperature should not exceed 52C (125F). Close valve after each use and when empty. Use in accordance with the Material Safety Data Sheet. Produced by Air Liquefaction Process.
FIRST AID: IN CASE OF FROSTBITE, obtain medical treatment immediately.
DO NOT REMOVE THIS PRODUCT LABEL.
CHEMTREC EMERGENCY NO. 1-800-424-9300
MELO’S GAS AND GEAR (661) 387-6800
MGG-USP
Oxygen, COMPRESSED USP UN1072
Oxygen 2 18033 (R 04/05)
WARNING: For emergency use only when administered by properly trained personnel for Oxygen deficiency and resuscitation. For all other medical applications, Rx only. Uninterrupted use of high concentrations of Oxygen over a long duration, without monitoring its effect on Oxygen content of arterial blood, may be harmful. Use only with pressure reducing equipment and apparatus designed for use with Oxygen. Do not attempt to use on patients who have stopped breathing, unless used in conjunction with resuscitative equipment. PRODUCED BY AIR LIQUEFACTION.
WARNING: HIGH PRESSURE OXIDIZING GAS. VIGOROUSLY ACCELERATES COMBUSTION. Keep oil and grease away. Open valve slowly. Store and use with adequate ventilation. Use only with equipment cleaned for Oxygen service and rated for cylinder pressure. Use a back flow preventive device in piping. Close valve after each use and when empty. Cylinder temperature should not exceed 52C (125F). Use in accordance with the Material Safety Data Sheet (MSDS).
CAS: 7782-44-7 DO NOT REMOVE THIS PRODUCT LABEL.
MELO’S GAS AND GEAR (661) 387-6800
Oxygen Oxygen gas | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
unapproved medical gas | 11/28/2011 |
Labeler - Melo's Gas and Gear, Inc. (782869080) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Melo's Gas and Gear, Inc. | 078373996 | manufacture |
Anaprilins may be available in the countries listed below.
Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Anaprilins in the following countries:
International Drug Name Search
Ketorolac Actavis may be available in the countries listed below.
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Ketorolac Actavis in the following countries:
International Drug Name Search
Sotalol GM may be available in the countries listed below.
Sotalol hydrochloride (a derivative of Sotalol) is reported as an ingredient of Sotalol GM in the following countries:
International Drug Name Search
Provinace may be available in the countries listed below.
Perindopril erbumine (a derivative of Perindopril) is reported as an ingredient of Provinace in the following countries:
International Drug Name Search
Relieving unproductive cough and reducing mucus in the chest due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.
Respi-Tann G Suspension is a cough suppressant and expectorant combination. The cough suppressant works in the brain to help decrease the cough reflex. The expectorant works by thinning mucus (phlegm) in the lungs, making it less sticky and easier to cough up. This makes coughs more productive.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Respi-Tann G Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Respi-Tann G Suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Respi-Tann G Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Respi-Tann G Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Respi-Tann G Suspension.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Drowsiness; dry mouth, nose, or throat; upset stomach.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Respi-Tann G side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include restlessness; seizures; severe agitation.
Store Respi-Tann G Suspension at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Respi-Tann G Suspension out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Respi-Tann G Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Haloperidol Iqfarma may be available in the countries listed below.
Haloperidol is reported as an ingredient of Haloperidol Iqfarma in the following countries:
International Drug Name Search
Ulobétasol may be available in the countries listed below.
Ulobétasol (DCF) is also known as Ulobetasol (Rec.INN)
International Drug Name Search
Glossary
DCF | Dénomination Commune Française |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Neurobloc may be available in the countries listed below.
UK matches:
Botulinum B Toxin is reported as an ingredient of Neurobloc in the following countries:
International Drug Name Search
Glossary
SPC | Summary of Product Characteristics (UK) |
Dexocort may be available in the countries listed below.
Desoximetasone is reported as an ingredient of Dexocort in the following countries:
International Drug Name Search
Exabetin may be available in the countries listed below.
Betamethasone is reported as an ingredient of Exabetin in the following countries:
Dexchlorpheniramine maleate (a derivative of Dexchlorpheniramine) is reported as an ingredient of Exabetin in the following countries:
International Drug Name Search
Floxsig may be available in the countries listed below.
Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Floxsig in the following countries:
International Drug Name Search
B05XA14
0001334-74-3
C3-H7-Na2-O6-P
216
Tonic
1,2,3-Propanetriol mono(dihydrogen phosphate) disodium salt
Disodium glycerol phosphate
International Drug Name Search
Glossary
PH | Pharmacopoeia Name |
Ergix douleur et fièvre may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Ergix douleur et fièvre in the following countries:
International Drug Name Search
Urapidil-Pharmore may be available in the countries listed below.
Urapidil is reported as an ingredient of Urapidil-Pharmore in the following countries:
International Drug Name Search
Revectina may be available in the countries listed below.
Ivermectin is reported as an ingredient of Revectina in the following countries:
International Drug Name Search
Lauromicina may be available in the countries listed below.
Erythromycin stearate (a derivative of Erythromycin) is reported as an ingredient of Lauromicina in the following countries:
International Drug Name Search
Fluconazol Redibag Baxter may be available in the countries listed below.
Fluconazole is reported as an ingredient of Fluconazol Redibag Baxter in the following countries:
International Drug Name Search
See also: Generic Paxil CR
Paxil is a brand name of paroxetine, approved by the FDA in the following formulation(s):
A generic version of Paxil has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Paxil and have been approved by the FDA:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paxil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Flumazénil Kabi may be available in the countries listed below.
Flumazenil is reported as an ingredient of Flumazénil Kabi in the following countries:
International Drug Name Search
Class: Antiallergic Agents
ATC Class: S01GX09
VA Class: OP900
Chemical Name: 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride
Molecular Formula: C21H23NO3•HCl
CAS Number: 140462-76-6
Brands: Patanol
Relatively selective histamine H1-receptor antagonist1 2 3 4 5 6 and mast-cell stabilizer.1 2 3 4 5 6 b
Temporary prevention of ocular itching associated with allergic conjunctivitis.1 2 13
Apply topically to the eye as an ophthalmic solution.1 Not for injection or oral use.1
If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.12
Avoid contamination of the solution container.1
Available as olopatadine hydrochloride; dosage expressed in terms of olopatadine.1
Children ≥3 years of age: 1 or 2 drops of a 0.1% solution in the affected eye(s) twice daily (at an interval of 6–8 hours).1
Once symptomatic improvement is established, continue therapy for as long as necessary to sustain improvement.12
1 or 2 drops of a 0.1% solution in the affected eye(s) twice daily (at an interval of 6–8 hours).1
Once symptomatic improvement is established, continue therapy for as long as necessary to sustain improvement.12
Known hypersensitivity to olopatadine or any ingredient in the formulation.1
Category C.1
Distributed into milk in rats following oral administration;1 not known whether distributed into human milk following topical application to the eye.1 Use with caution.1
Safety and efficacy not established in children <3 years of age.1
Appears to be well-tolerated in children 3–16 years of age.11 13
No substantial differences in safety and efficacy relative to younger adults.a
Headache.1 2 13
No formal drug interaction studies to date.12
Limited systemic exposure following topical application to the eye;1 plasma concentrations usually are undetectable.1 12 13
Rapid onset;3 13 14 15 symptomatic relief of itching generally occurs within 30 minutes.12 13 15
Long duration (≥8 hours).3 13 14 15
Distribution into human ocular tissues and fluids not characterized.1
Metabolized in the liver to monodesmethyl olopatadine and olopatadine N-oxide following topical application to the eyes.1 12
Eliminated principally by renal excretion; 60–70% of systemically absorbed dose excreted in urine as parent drug.1 12
Approximately 3 hours following topical application to the eyes.1
4–25°C.1
Inhibits type I immediate hypersensitivity reactions in vitro and in vivo.1 3
Suppresses the release of inflammatory mediators (e.g., histamine, prostaglandin D2, tryptase) in response to antigenic stimulation of human conjunctival mast cells in a dose-dependent manner.5 13
Inhibits histamine-stimulated conjunctival vascular permeability response in a concentration-dependent manner.3
Potency is comparable to that of levocabastine and exceeds that of pheniramine or antazoline.3 13
Importance of learning and adhering to proper administration techniques to avoid contamination of the solution container.1 12
Importance of removing soft contact lenses prior to administration of each dose.1 Delay reinsertion for 10 minutes after administration if eyes are not red; do not wear contact lenses if eye(s) are red.1 12 Not indicated for contact lens-related irritation.1
Importance of administering different topical ophthalmic preparations at least 5 minutes apart.12
Importance of patients informing clinicians of exisiting or contemplated therapy, including prescription and OTC drugs.
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.a
Importance of informing patients of other important precautionary information.a (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Solution | 0.1% (of olopatadine) | Patanol (with benzalkonium chloride) | Alcon |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Pataday 0.2% Solution (ALCON VISION): 2/$119.99 or 7/$334.98
Patanol 0.1% Solution (ALCON VISION): 5/$125.99 or 15/$359.99
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2004. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Alcon Laboratories. Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% prescribing information. Fort Worth, TX; 1996 Dec.
2. Anon. Olopatadine for allergic conjunctivitis. Med Lett Drugs Ther. 1997; 39:108-9. [PubMed 9398823]
3. Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996; 12:389-400. [PubMed 8951675]
4. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996; 12:401-7. [PubMed 8951676]
5. Sharif NA, Xu SX, Miller ST et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996; 278:1252-61. [PubMed 8819509]
6. Kamei C, Sugimoto Y, Nakamura S et al. Effect of (Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs. Arzneimittelforschung. 1995; 45:1005-8. [PubMed 7488300]
7. Ciprandi G, Buscaglia S, Cerqueti PM et al. Drug treatment of allergic conjunctivitis: a review of the evidence. Drugs. 1992; 43:154-76. [IDIS 360840] [PubMed 1372215]
8. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998; 57:735-46. [IDIS 418448] [PubMed 9490996]
9. Titi MJ. A critical look at ocular allergy drugs. Am Fam Physician. 1996; 53:2637-42. [IDIS 367250] [PubMed 8644576]
10. Galindez OA, Kaufman HE. Coping with the itchy-burnies: the management of allergic conjunctivitis. Ophthalmology. 1996; 103:1335-6. [IDIS 373485] [PubMed 8841290]
11. Reviewers’ comments (personal observations).
12. Alcon Laboratories; Fort Worth, TX: Personal communication.
13. Alcon Laboratories. Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% product monograph. Fort Worth, TX: (not dated).
14. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998; 125:797-804. [IDIS 409293] [PubMed 9645717]
15. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998; 81:211-8. [IDIS 415165] [PubMed 9759796]
a. Alcon Laboratories. Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% prescribing information. Fort Worth, TX; 2003 Dec.
b. Anon. New drugs for allergic conjunctivitis. Med Lett Drugs Ther. 2000; 42:39-40. [PubMed 10825920]
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
0007361-61-7
C12-H16-N2-S
220
Sedative agent
Analgesic
Muscle relaxant
4H-1,3-Thiazin-2-amine, N-(2,6-dimethylphenyl)-5,6-dihydro-
International Drug Name Search
Glossary
BAN | British Approved Name |
BANM | British Approved Name (Modified) |
IS | Inofficial Synonym |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Benzacne may be available in the countries listed below.
Benzoyl Peroxide is reported as an ingredient of Benzacne in the following countries:
International Drug Name Search
1.1. Skin slackening
1.2. Tissue revitalization
1.3. Gluteal muscle tone.
2.1. Treatment for IM application: 1 vial 1-3 times a week according to severity and clinic evolution.
2.2. Treatment using mesotherapy technique: Apply 0.3 ml for each point. Using a 13 mm, 30G or a 4 mm, 27G needle, make the classic intradermal injections utilizing mesotherapy technique.
Application points: Apply to the affected area (abdomen, upper and lower extremities, gluteus muscles). Gluteus muscles: from the center of the gluteus muscle proceed along 4 injection lines, in a sunburst shape; apply along the subgluteal furrow.
Standard protocol consists of one session a week for 5-7 weeks. For prolonged treatments, 2 sessions for the first week, 1 session a week for 1 month and then 1 session a month are recommended.
Discard unused solution.
2.3. Opening of Vials: Use sterile needles and sterile syringe. Do not reuse. Do not use if foreign particles are present. Draw 1 cc of air into syringe, insert needle into vial inject air and withdraw the solution into the syringe
3.1. Injectable solution for subcutaneneous, intradermal, or intramuscular administration.
Pharmaceutical forms: 2 ml glass vials.
3.2. Each ingredient is attenuated according to the Homeopathic Pharmacopea of United States.
Active ingredients: a-Ketoglutaricum acidum 6X; Barium oxalosuccinate 6X; Calcarea carbonica 6X; Calcarea carbonica 30X; Calcarea carbonica 200X; Cis-Aconitic acid 6X; Citricum acidum 6X; Cyclamen europaeum 6X; DL malic acid 6X; Embryo 6X; Fumaricum acidum 6X; Funiculus umbilicalis 6X; Isoleucine 6X; Leucine 6X; Lysine 6X; Magnesium gluconate 6X; Manganum phosphoricum 6X; Methionine 6X; Natrum pyruvicum 6X; Natrum sulphuricum 6X; Nicotinamidum 6X; Phenylalanine 6X; Placenta 10X; Pulsatilla 6X; Succinicum acidum 6X; Threonine 6X; Thuja occidentalis 6X; Tryptophan 6X; Valine 6X.
Inactive ingredient: Sterile isotonic sodium chloride solution.
4.1. There is no history of hypersensitivity to OMEOFORMULA®3-TISSUE TONE. However patients with a known hypersensitivity to any ingredient should be tested before use. Make a spot injection (0.1ml) into the forearm and observe for any reactions for 1 hour.
5.1. Be sure to disinfect the area before application. Skin disinfection helps avoid infection at the site of administration that can result from saprophytic bacteria (i.e. atypical mycobacteria, staphylococcus genus) that may be present on the skin.
6.1. The most common mild adverse reaction is slight reddening at the injection site due to the mechanical effect of the needle or a superficial skin reaction of mild erythema.
7.1. None Known.
8.1 Pregnancy: Pregnancy category C. Animal reproduction studies have not been conducted with OMEOFORMULA®3-TISSUE TONE. OMEOFORMULA®3-TISSUE TONE should not be administered to a pregnant woman.
8.2 Nursing mothers: It is not known whether any of the ingredients in OMEOFORMULA®3-TISSUE TONE are secreted in human milk. However, since many drugs are secreted in human milk, caution should be exercised when OMEOFORMULA®3-TISSUE TONE is administered to a nursing woman.
8.3 Pediatric use: Effectiveness in pediatric patients has not been established.
8.4 Geriatric use: No restrictions.
9.1. No Known.
10.1. No Known.
OMEOFORMULA®3- TISSUE TONE is a sterile solution made with isotonic sodium chloride solution. Its formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred to in Materia Medica.
The firming and toning activity is due to the activity of the suis-organ ingredients. The amino acid ingredients promote protein synthesis.
12.1. Mechanism of Action
The medication acts through a low-dose enzymatic mechanism.
12.2. Pharmacodynamics
The physiological effects of OMEOFORMULA®3- TISSUE TONE are due to the effects of the ingredients, according to their description in the Homeopathic Materia Medica.
12.3. Pharmacokinetics
Homeopathic attenuation provides complete bioavability of the active ingredients.
13.1. OMEOFORMULA®3- TISSUE TONE has no level of toxicity due to the attenuation of the ingredients.
14.1. OMEOFORMULA®3- TISSUE TONE formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred in Materia Medica.
15.1. E.Italia, M. De Bellis: Manuale di Omeo-mesoterapia – Guna Ed. 1995
15.2. H.H. Reckeweg: Homeopathic Materia medica omeopatica. Aurelia Verlag.
17.1. Patients should be informed of the homeopathic approach and the therapeutic goals of OMEOFORMULA®3- TISSUE TONE.
OMEOFORMULA 3-TISSUE TONE .alpha.-ketoglutaric acid - aconitic acid, cis - barium cation - calcium carbonate - citric acid monohydrate - cyclamen purpurascens tuber - fumaric acid - isoleucine - leucine - lysine - magnesium gluconate - malic acid - manganese phosphate, dibasic - methionine - natrum sulphuricum - niacinamide - phenylalanine - pulsatilla vulgaris - sodium pyruvate - succinic acid - sus scrofa placenta - sus scrofa umbilical cord - threonine - thuja occidentalis twig - tryptophan - valine - sus scrofa embryo - injection, solution | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
unapproved homeopathic | 09/29/2006 |
Labeler - Guna spa (430538264) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Guna spa | 430538264 | manufacture |
Uralyt Urato may be available in the countries listed below.
Potassium Citrate is reported as an ingredient of Uralyt Urato in the following countries:
International Drug Name Search
Zuracyn may be available in the countries listed below.
Erythromycin is reported as an ingredient of Zuracyn in the following countries:
International Drug Name Search
Armolev may be available in the countries listed below.
Levofloxacin is reported as an ingredient of Armolev in the following countries:
International Drug Name Search
Juvisync is a brand name of simvastatin/sitagliptin, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Juvisync available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Juvisync. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.